13. Dezember 2012 / by Elke Setzer / 2012
Constance, Germany– Following the successful market launch of the PrenaTest® in Germany, Austria, Liechtenstein and Switzerland, Europe’s first non-invasive molecular genetic blood test for the detection of fetal trisomy 21 from maternal blood is now available in selected gynecologic practices and prenatal diagnostic clinics in Hungary, Bulgaria, Ukraine, Russia and Turkey.
Read more
PrenaTest® is now available in over 30 countries in Europe, Middle East and Asia
13. Dezember 2012 / by Elke Setzer / 2012
Constance, Germany– Following the successful market launch of the PrenaTest® in Germany, Austria, Liechtenstein and Switzerland, Europe’s first non-invasive molecular genetic blood test for the detection of fetal trisomy 21 from maternal blood is now available in selected gynecologic practices and prenatal diagnostic clinics in Hungary, Bulgaria, Ukraine, Russia and Turkey.
Read more
About 1,000 women have opted for PrenaTest® since market launch
15. November 2012 / by Elke Setzer / 2012
Constance, Germany – In the first three months after market launch, close to 1,000 pregnant women have opted for the PrenaTest®, Europe’s first non-invasive molecular genetic blood test for the detection of fetal trisomy 21. All of them were at risk for trisomy 21 in the unborn child.
Read more
PrenaTest® now available in Germany, Austria, Liechtenstein and Switzerland
20. August 2012 / by Elke Setzer / 2012
Constance, Germany – As of today, PrenaTest® is available in more than 70 qualified prenatal diagnostic practices and clinics in Germany, Austria, Liechtenstein and Switzerland.
PrenaTest® is a highly accurate non-invasive genetic blood test which is intended for use among women with pregnancies at high risk for fetal aneuploidy, specifically to detect fetal trisomy 21
Read more
GATC daughter LifeCodexx successfully completes clinical validation of its noninvasive prenatal test method of trisomy 21
27. April 2012 / by Elke Setzer / 2012
Constance, Germany – GATC daughter LifeCodexx AG today announced the successful completion of the clinical validation study of its noninvasive test method for the detection of fetal trisomy 21 from maternal blood using Next Generation sequencing. First results from the prospective blinded multi-center study demonstrate highest clinical accuracy for the planned commercial PrenaTest® test design based on Cell-Free DNA® blood collection tubes (BCT), detecting all positive cases of fetal trisomy 21 (100% sensitivity) with no false positive calls (100% specificity).
Read more
GATC Biotech and LifeCodexx complete recruitment of blood samples for clinical study of trisomy 21 diagnostic test
10. Januar 2012 / by Elke Setzer / 2012
Constance, Germany – GATC Biotech AG and its subsidiary LifeCodexx AG successfully completed the recruitment of over 500 blood samples required for the clinical study of the non-invasive prenatal diagnostic test for the determination of trisomy 21 (LifeCodexx PrenaTest®). The prospective and blinded study evaluates this new molecular genetic method in comparison with conventional invasive methods and is based on the Next Generation sequencing of cell-free fetal DNA from maternal blood.
Read more